Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 14, 2025, regarding events reported on October 13, 2025. Theriva Biologics, Inc., a Nevada corporation, announced the upcoming presentation of expanded clinical data for its lead candidate, VCN-01, at the European Society for Medical Oncology (ESMO) 2025 Annual Congress on October 20, 2025. The filing also notes a separate poster presentation regarding SYN-004 (ribaxamase) at IDWeek 2025.
Key Clinical Metrics and Trial Results
The filing details results from the VIRAGE Phase 2b trial (NCT05673811) evaluating VCN-01 in combination with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel, or GA) for metastatic pancreatic ductal adenocarcinoma (mPDAC). The study randomized 112 patients. Key metrics from the Full Analysis Set (FAS) and Modified Intent-to-Treat (mITT) populations include:
| Metric | Arm I (GA Alone) | Arm II (VCN-01 + GA) | Hazard Ratio (95% CI) | P-Value |
|---|---|---|---|---|
| Overall Survival (OS) - FAS | 8.6 months | 10.8 months | 0.57 (0.34-0.96) | 0.055 |
| Progression-Free Survival (PFS) - FAS | 4.6 months | 7.0 months | 0.55 (0.34-0.88) | 0.011 |
| Duration of Response (DoR) | 5.4 months | 11.2 months | 0.22 (0.08-0.62) | 0.004 |
| Objective Response Rate (ORR) - FAS | 31.3% | 39.6% | N/A | N/A |
In a specific subgroup analysis comparing patients starting GA cycle 4 alone versus those receiving two VCN-01 doses prior to GA cycle 4, the combination arm showed statistically significant improvements: OS of 14.8 vs 11.6 months (HR 0.44, P=0.046) and PFS of 11.2 vs 7.4 months (HR 0.48, P=0.017).
Material Changes and Safety Profile
The study met its primary endpoints, demonstrating improved OS, PFS, and DoR for patients receiving VCN-01 plus GA compared to GA standard of care. VCN-01 was reported as well-tolerated. All 13 VCN-01-related serious adverse events were resolved. The most common adverse events included flu-like symptoms (13.2%), transaminase increase (5.7%), and drug-induced liver injury (3.8%). Viral genome analysis confirmed the bioactivity of the second VCN-01 dose.
Guidance, Outlook, and Risks
Management indicated that the expanded data will be presented at ESMO 2025. The filing includes "safe harbor" language regarding forward-looking statements. No specific financial guidance, revenue projections, or liquidity updates were provided in this filing. The filing explicitly states that the information in Item 7.01 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the full abstract of the VIRAGE trial filed as Exhibit 99.2 for complete statistical methodology.
- Confirm the specific date and time of the ESMO 2025 presentation on October 20, 2025.
- Review the safety data regarding drug-induced liver injury and transaminase increases in the full clinical report.
- Check for subsequent filings regarding the SYN-004 (ribaxamase) data presentation at IDWeek 2025.
- Monitor the company's cash position and funding status, as this 8-K does not contain financial statements or liquidity metrics.